Key result
Concurrent heart failure and COPD compound diagnostic challenges and markedly increase morbidity, mortality, and costs.
Why the study?
Concurrent chronic obstructive pulmonary disease in patients with heart failure presents diagnostic and therapeutic challenges and increases morbidity and mortality, requiring further validation of strategies.
Concurrent heart failure and COPD present significant diagnostic and therapeutic challenges, highlighting the need for validated strategies to manage this multimorbidity.
Pulmonary disease is common in patients with heart failure, through shared risk factors and pathophysiological mechanisms. Adverse pulmonary vascular remodelling and chronic systemic inflammation characterize both diseases. Concurrent chronic obstructive pulmonary disease presents diagnostic and therapeutic challenges, and is associated with increased morbidity and mortality. The cornerstones of therapy are beta-blockers and beta-agonists, whose pharmacological properties are diametrically opposed. Each disease is implicated in exacerbations of the other condition, greatly increasing hospitalizations and associated health care costs. Such multimorbidity is a key challenge for health-care systems oriented towards the treatment of individual diseases. Early identification and treatment of cardiopulmonary disease may alleviate this burden. However, diagnostic and therapeutic strategies require further validation in patients with both conditions.
No takes yet. Share an insight, caveat, or question.
Hawkins et al. (2013) conducted a review in Heart failure and chronic obstructive pulmonary disease. Concurrent heart failure and chronic obstructive pulmonary disease present significant diagnostic and therapeutic challenges, increasing morbidity, mortality, and healthcare costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: